Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris: A Single Arm, Open-label Exploratory Trial
Phase of Trial: Phase I
Latest Information Update: 13 Dec 2018
At a glance
- Drugs Secukinumab (Primary)
- Indications Pityriasis rubra pilaris
- Focus Therapeutic Use
- 20 Mar 2018 Planned End Date changed from 30 Nov 2020 to 15 Apr 2020.
- 20 Mar 2018 Planned primary completion date changed from 30 Nov 2019 to 15 Apr 2019.
- 20 Mar 2018 Status changed from not yet recruiting to recruiting.